Selected article for: "adaptive immune system and host defense"
Author: Acosta, Patricio L.; Byrne, Alana B.; Hijano, Diego R.; Talarico, Laura B.
Title: Human Type I Interferon Antiviral Effects in Respiratory and Reemerging Viral Infections
  • Cord-id: fkfuivj3
  • Document date: 2020_5_8
    • ID: fkfuivj3
    Snippet: Type I interferons (IFN-I) are a group of related proteins that help regulate the activity of the immune system and play a key role in host defense against viral infections. Upon infection, the IFN-I are rapidly secreted and induce a wide range of effects that not only act upon innate immune cells but also modulate the adaptive immune system. While IFN-I and many IFN stimulated genes are well-known for their protective antiviral role, recent studies have associated them with potential pathogenic
    Document: Type I interferons (IFN-I) are a group of related proteins that help regulate the activity of the immune system and play a key role in host defense against viral infections. Upon infection, the IFN-I are rapidly secreted and induce a wide range of effects that not only act upon innate immune cells but also modulate the adaptive immune system. While IFN-I and many IFN stimulated genes are well-known for their protective antiviral role, recent studies have associated them with potential pathogenic functions. In this review, we summarize the current knowledge regarding the complex effects of human IFN-I responses in respiratory as well as reemerging flavivirus infections of public health significance and the molecular mechanisms by which viral proteins antagonize the establishment of an antiviral host defense. Antiviral effects and immune modulation of IFN-stimulated genes is discussed in resisting and controlling pathogens. Understanding the mechanisms of these processes will be crucial in determining how viral replication can be effectively controlled and in developing safe and effective vaccines and novel therapeutic strategies.

    Search related documents:
    Co phrase search for related documents
    • action mode and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45
    • action mode and adaptive immune system: 1, 2
    • action mode and administration route: 1, 2, 3
    • action mode and lung disease: 1, 2
    • action mode and lysosome endosome: 1
    • activation inhibit and acute phase: 1
    • activation inhibit and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • activation inhibit and adaptive immune response: 1, 2
    • activation inhibit and adenosine deaminase: 1
    • activation inhibit and lung epithelial cell: 1
    • activation inhibit and lysosome endosome: 1
    • activation lead and acute phase: 1
    • activation lead and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • activation lead and adaptive immune response: 1, 2, 3, 4
    • activation lead and adaptive immune system: 1
    • activation lead and adenosine deaminase: 1
    • activation lead and lung disease: 1, 2, 3, 4, 5
    • activation lead and lung epithelial cell: 1
    • activation pathway and acute phase: 1, 2, 3, 4, 5